253G2 1 tm2032035d2_253g2.htm 253G2

 

Filed Pursuant to Rule 253(g)(2)

File No. 024-11137

 

EXPLANATORY NOTE

 

This is a supplement to the offering circular of Scopus BioPharma Inc. (the “Company”) dated February 4, 2020 (the “Offering Circular”), available at https://www.sec.gov/Archives/edgar/data/1772028/000110465920013793/tv538014-253g1.htm.

 

Additional information about the Company is available in its annual report on Form 1-K for the fiscal year ended December 31, 2019, available at https://www.sec.gov/Archives/edgar/data/1772028/000110465920062617/tm2019379-1_partii.htm and its Form 1-U filed on June 11, 2020, available at https://www.sec.gov/Archives/edgar/data/1772028/000110465920072314/tm2022341-1_1u.htm, both of which were previously incorporated by reference into the Offering Circular via supplements.

 

 

SUPPLEMENT NO. 3 DATED SEPTEMBER 29, 2020

TO OFFERING CIRCULAR DATED FEBRUARY 4, 2020

 

 

This supplement to the Offering Circular supplements the Offering Circular by incorporating by reference our semiannual report on Form 1-SA dated September 25, 2020 for the six months ended June 30, 2020, available at https://www.sec.gov/Archives/edgar/data/1772028/000110465920108780/tm2031357d1_1sa.htm.

 

The Securities and Exchange Commission (“SEC”) allows us to incorporate by reference into the Offering Circular certain information in documents we file with the SEC, which means that we can disclose important information by referring you to such referenced documents. The information incorporated by reference is considered to be a part of the Offering Circular. This supplement to the Offering Circular should be read in conjunction with the Offering Circular.